Payment overview · 2025
General Payments
$1,261.03
34 reported records · 14 companies
Healthcare provider profile · identity verified
Joseph Ravid, M.D.
Allopathic & Osteopathic Physicians|Family Medicine · PORT CHARLOTTE, FL · NPI 1548466519
Verified facts
What the public records show
CMS Open Payments records show Joseph Ravid, M.D. received $1,261.03 in general payments during 2025 across 34 reported records.
Corcept Therapeutics accounted for 34.6% of that reported general-payment amount.
The Open Payments records used for this analysis explicitly named 17 associated products.
A separate comparison found the same explicitly named product in public Medicare Part D data: Eliquis, Ozempic, Rybelsus.
Lilly USA, LLC reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported JARDIANCE as an associated drug or biological on 47708 records involving 23833 distinct recipient NPIs. Public Medicare Part D data also shows 15 claims for Jardiance by this doctor in 2024.
Lilly USA, LLC reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported TRULICITY as an associated drug or biological on 71 records involving 57 distinct recipient NPIs. Public Medicare Part D data also shows 23 claims for Trulicity by this doctor in 2024.
Novo Nordisk Inc reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported Ozempic as an associated drug or biological on 261625 records involving 77793 distinct recipient NPIs. Public Medicare Part D data also shows 73 claims for Ozempic by this doctor in 2024.
Novo Nordisk Inc reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported Rybelsus as an associated drug or biological on 161257 records involving 55409 distinct recipient NPIs. Public Medicare Part D data also shows 16 claims for Rybelsus by this doctor in 2024.
PFIZER INC. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported ELIQUIS as an associated drug or biological on 87112 records involving 36032 distinct recipient NPIs. Public Medicare Part D data also shows 64 claims for Eliquis by this doctor in 2024.
These records do not establish that a payment influenced prescribing or medical care.
Separate record types
Research & Ownership
Research Payments (direct recipient): not present in the loaded data
Associated Research Funding (for example, named PI): not present in the loaded data
Ownership / Investment: not present in the loaded data
These categories are never added into the General Payments headline. Associated research funding must not be described as money the doctor personally received unless the source record supports that conclusion.
Who paid this doctor?
Companies in 2025 General Payments
| Reported company | Canonical company | Amount | Share | Records | Year |
|---|---|---|---|---|---|
| Corcept Therapeutics | Unresolved — no canonical attribution shown | $436.94 | 34.6% | 2 | 2025 |
| Novo Nordisk Inc | Unresolved — no canonical attribution shown | $167.73 | 13.3% | 9 | 2025 |
| Phathom Pharmaceuticals, Inc. | Unresolved — no canonical attribution shown | $159.03 | 12.6% | 2 | 2025 |
| Sumitomo Pharma America, Inc. | Unresolved — no canonical attribution shown | $123.50 | 9.8% | 5 | 2025 |
| Lilly USA, LLC | Unresolved — no canonical attribution shown | $76.01 | 6.0% | 3 | 2025 |
| Astellas Pharma US Inc | Unresolved — no canonical attribution shown | $70.50 | 5.6% | 3 | 2025 |
| Abbott Laboratories | Unresolved — no canonical attribution shown | $48.19 | 3.8% | 2 | 2025 |
| Otsuka America Pharmaceutical, Inc. | Unresolved — no canonical attribution shown | $39.10 | 3.1% | 2 | 2025 |
| Dexcom, Inc. | Unresolved — no canonical attribution shown | $31.94 | 2.5% | 1 | 2025 |
| Exact Sciences Corporation | Unresolved — no canonical attribution shown | $29.25 | 2.3% | 1 | 2025 |
| Axsome Therapeutics, Inc. | Unresolved — no canonical attribution shown | $23.97 | 1.9% | 1 | 2025 |
| Esperion Therapeutics, Inc. | Unresolved — no canonical attribution shown | $19.99 | 1.6% | 1 | 2025 |
| Acella Pharmaceuticals, LLC | Unresolved — no canonical attribution shown | $18.59 | 1.5% | 1 | 2025 |
| PFIZER INC. | Unresolved — no canonical attribution shown | $16.29 | 1.3% | 1 | 2025 |
What were the payments for?
Payment categories
| Category | Amount | Records |
|---|---|---|
| Food and Beverage | $1,016.03 | 33 |
| Travel and Lodging | $245.00 | 1 |
A meal, consulting fee, royalty, and travel payment describe different kinds of reported relationships and should not be interpreted as equivalent.
Analysis 1 · Payment-linked products
Products named in Open Payments records
| Reported product | Type | Reported company | Related amount* | Records | Year |
|---|---|---|---|---|---|
| Ozempic Normalized: ozempic |
Drug | Novo Nordisk Inc | $167.73 | 9 | 2025 |
Source payment records
|
|||||
| VOQUEZNA Normalized: voquezna |
Drug | Phathom Pharmaceuticals, Inc. | $159.03 | 2 | 2025 |
Source payment records
|
|||||
| GEMTESA Normalized: gemtesa |
Drug | Sumitomo Pharma America, Inc. | $123.50 | 5 | 2025 |
Source payment records
|
|||||
| Rybelsus Normalized: rybelsus |
Drug | Novo Nordisk Inc | $113.50 | 6 | 2025 |
Source payment records
|
|||||
| Veozah Normalized: veozah |
Drug | Astellas Pharma US Inc | $70.50 | 3 | 2025 |
Source payment records
|
|||||
| MOUNJARO Normalized: mounjaro |
Drug | Lilly USA, LLC | $44.22 | 2 | 2025 |
Source payment records
|
|||||
| ZEPBOUND Normalized: zepbound |
Drug | Lilly USA, LLC | $44.22 | 2 | 2025 |
Source payment records
|
|||||
| REXULTI Normalized: rexulti |
Drug | Otsuka America Pharmaceutical, Inc. | $39.10 | 2 | 2025 |
Source payment records
|
|||||
| Dexcom G6 Transmitter Normalized: dexcom g6 transmitter |
Medical Supply | Dexcom, Inc. | $31.94 | 1 | 2025 |
Source payment records
|
|||||
| Cologuard Collection Kit Normalized: cologuard collection kit |
Device | Exact Sciences Corporation | $29.25 | 1 | 2025 |
Source payment records
|
|||||
| JOT DX Normalized: jot dx |
Device | Abbott Laboratories | $24.87 | 1 | 2025 |
Source payment records
|
|||||
| Auvelity Normalized: auvelity |
Drug | Axsome Therapeutics, Inc. | $23.97 | 1 | 2025 |
Source payment records
|
|||||
| FREESTYLE LIBRE 3 Normalized: freestyle libre 3 |
Device | Abbott Laboratories | $23.32 | 1 | 2025 |
Source payment records
|
|||||
| NEXLETOL Normalized: nexletol |
Drug | Esperion Therapeutics, Inc. | $19.99 | 1 | 2025 |
Source payment records
|
|||||
| NP Thyroid 60 Normalized: np thyroid 60 |
Drug | Acella Pharmaceuticals, LLC | $18.59 | 1 | 2025 |
Source payment records
|
|||||
| ELIQUIS Normalized: eliquis |
Drug | PFIZER INC. | $16.29 | 1 | 2025 |
Source payment records
|
|||||
| NURTEC ODT Normalized: nurtec odt |
Drug | PFIZER INC. | $16.29 | 1 | 2025 |
Source payment records
|
|||||
* Product-associated amounts are non-additive because one payment record may name more than one product.
These products were named on specific Open Payments records. A named product does not show that the payment influenced treatment or prescribing.
Public prescribing for products named in payments
| Open Payments product | Payment year | Part D brand | Part D year | Claims | Match method | Source |
|---|---|---|---|---|---|---|
| ELIQUIS eliquis |
2025 | Eliquis | 2024 | 64 | exact normalized | Medicare Part D |
| Ozempic ozempic |
2025 | Ozempic | 2024 | 73 | exact normalized | Medicare Part D |
| Rybelsus rybelsus |
2025 | Rybelsus | 2024 | 16 Beneficiary count suppressed |
exact normalized | Medicare Part D |
The presence of the same drug in both datasets does not show that a payment caused or influenced a prescription.
Analysis 2 · Same-company prescribing overlap
Drugs reported in other payments from the same company that also appear in Medicare Part D
This analysis is independent from products named on this doctor’s individual payment records. A row appears only when the exact Open Payments reporting entity paid this doctor, that same reporting entity reported the drug or biological on at least 10 loaded General Payment records involving at least 2 distinct recipient NPIs, and this doctor has the same non-generic brand in public Part D data. This does not mean the company owns or manufactures the drug.
| Paying company | Payment year | Drug reported by same entity | Open Payments evidence | Part D | Claims | Beneficiaries |
|---|---|---|---|---|---|---|
| Lilly USA, LLC Exact reporting entity; no affiliate inference |
2025 | JARDIANCE open payments reported associated product |
CMS Open Payments — General Payments 47708 supporting records · 23833 recipient NPIs · example record 1186464557 |
Jardiance · 2024 Exact normalized brand match · 1 Part D row |
15 | suppressed by CMS |
| Lilly USA, LLC Exact reporting entity; no affiliate inference |
2025 | TRULICITY open payments reported associated product |
CMS Open Payments — General Payments 71 supporting records · 57 recipient NPIs · example record 1186464601 |
Trulicity · 2024 Exact normalized brand match · 1 Part D row |
23 | suppressed by CMS |
| Novo Nordisk Inc Exact reporting entity; no affiliate inference |
2025 | Ozempic open payments reported associated product |
CMS Open Payments — General Payments 261625 supporting records · 77793 recipient NPIs · example record 1188130076 |
Ozempic · 2024 Exact normalized brand match · 1 Part D row |
73 | 17 |
| Novo Nordisk Inc Exact reporting entity; no affiliate inference |
2025 | Rybelsus open payments reported associated product |
CMS Open Payments — General Payments 161257 supporting records · 55409 recipient NPIs · example record 1188130076 |
Rybelsus · 2024 Exact normalized brand match · 1 Part D row |
16 | suppressed by CMS |
| PFIZER INC. Exact reporting entity; no affiliate inference |
2025 | ELIQUIS open payments reported associated product |
CMS Open Payments — General Payments 87112 supporting records · 36032 recipient NPIs · example record 1228794063 |
Eliquis · 2024 Exact normalized brand match · 1 Part D row |
64 | 17 |
These facts do not show that a payment was for the drug, that the company owns or manufactures the drug, or that a payment caused or influenced prescribing.
Public Medicare Part D data
Provider-and-drug rows loaded for 2024
| Brand | Generic | Claims | Beneficiaries |
|---|---|---|---|
| Levothyroxine Sodium | Levothyroxine Sodium | 451 | 121 |
| Atorvastatin Calcium | Atorvastatin Calcium | 287 | 81 |
| Lisinopril | Lisinopril | 286 | 72 |
| Rosuvastatin Calcium | Rosuvastatin Calcium | 249 | 67 |
| Simvastatin | Simvastatin | 221 | 64 |
| Amlodipine Besylate | Amlodipine Besylate | 189 | 58 |
| Losartan Potassium | Losartan Potassium | 188 | 57 |
| Alprazolam | Alprazolam | 173 | 47 |
| Metformin Hcl | Metformin Hcl | 159 | 50 |
| Metoprolol Tartrate | Metoprolol Tartrate | 159 | 47 |
| Hydrochlorothiazide | Hydrochlorothiazide | 150 | 48 |
| Pantoprazole Sodium | Pantoprazole Sodium | 130 | 42 |
| Allopurinol | Allopurinol | 125 | 31 |
| Omeprazole | Omeprazole | 121 | 32 |
| Potassium Chloride | Potassium Chloride | 96 | 21 |
| Progesterone | Progesterone, Micronized | 90 | 28 |
| Trazodone Hcl | Trazodone Hcl | 89 | 21 |
| Metoprolol Succinate | Metoprolol Succinate | 86 | 25 |
| Furosemide | Furosemide | 78 | 23 |
| Fluoxetine Hcl | Fluoxetine Hcl | 75 | 26 |
| Ozempic | Semaglutide | 73 | 17 |
| Hydrocodone-Acetaminophen | Hydrocodone/Acetaminophen | 71 | suppressed |
| Gabapentin | Gabapentin | 68 | 19 |
| Tamsulosin Hcl | Tamsulosin Hcl | 68 | 24 |
| Eliquis | Apixaban | 64 | 17 |
| Carvedilol | Carvedilol | 61 | 13 |
| Escitalopram Oxalate | Escitalopram Oxalate | 61 | 17 |
| Lovastatin | Lovastatin | 61 | 14 |
| Quetiapine Fumarate | Quetiapine Fumarate | 55 | suppressed |
| Clopidogrel | Clopidogrel Bisulfate | 54 | 18 |
| Meloxicam | Meloxicam | 52 | 13 |
| Tramadol Hcl | Tramadol Hcl | 52 | 18 |
| Montelukast Sodium | Montelukast Sodium | 50 | 12 |
| Famotidine | Famotidine | 49 | suppressed |
| Oxycodone-Acetaminophen | Oxycodone Hcl/Acetaminophen | 47 | 11 |
| Citalopram Hbr | Citalopram Hydrobromide | 44 | suppressed |
| Glimepiride | Glimepiride | 43 | 11 |
| Mirtazapine | Mirtazapine | 43 | suppressed |
| Ezetimibe | Ezetimibe | 42 | 12 |
| Farxiga | Dapagliflozin Propanediol | 41 | suppressed |
| Sertraline Hcl | Sertraline Hcl | 41 | suppressed |
| Atenolol | Atenolol | 39 | suppressed |
| Finasteride | Finasteride | 39 | 11 |
| Losartan-Hydrochlorothiazide | Losartan/Hydrochlorothiazide | 38 | suppressed |
| Spironolactone | Spironolactone | 38 | 12 |
| Fenofibrate | Fenofibrate Nanocrystallized | 37 | suppressed |
| Zolpidem Tartrate | Zolpidem Tartrate | 37 | 16 |
| Lisinopril-Hydrochlorothiazide | Lisinopril/Hydrochlorothiazide | 36 | 11 |
| Celecoxib | Celecoxib | 35 | 12 |
| Divalproex Sodium | Divalproex Sodium | 34 | suppressed |
| Synthroid | Levothyroxine Sodium | 34 | suppressed |
| Testosterone Cypionate | Testosterone Cypionate | 33 | 11 |
| Donepezil Hcl | Donepezil Hcl | 32 | suppressed |
| Lorazepam | Lorazepam | 32 | suppressed |
| Fentanyl | Fentanyl | 30 | suppressed |
| Ibuprofen | Ibuprofen | 30 | suppressed |
| Oxybutynin Chloride | Oxybutynin Chloride | 30 | suppressed |
| Prednisone | Prednisone | 30 | 13 |
| Np Thyroid | Thyroid,pork | 29 | suppressed |
| Warfarin Sodium | Warfarin Sodium | 28 | suppressed |
| Januvia | Sitagliptin Phosphate | 27 | suppressed |
| Pravastatin Sodium | Pravastatin Sodium | 27 | suppressed |
| Jantoven | Warfarin Sodium | 26 | suppressed |
| Clonazepam | Clonazepam | 25 | suppressed |
| Fluticasone Propionate | Fluticasone Propionate | 24 | 11 |
| Memantine Hcl | Memantine Hcl | 24 | suppressed |
| Metformin Hcl Er | Metformin Hcl | 24 | suppressed |
| Liothyronine Sodium | Liothyronine Sodium | 23 | suppressed |
| Oxycodone Hcl | Oxycodone Hcl | 23 | suppressed |
| Paroxetine Hcl | Paroxetine Hcl | 23 | suppressed |
| Trulicity | Dulaglutide | 23 | suppressed |
| Alendronate Sodium | Alendronate Sodium | 22 | suppressed |
| Olmesartan Medoxomil | Olmesartan Medoxomil | 22 | suppressed |
| Propranolol Hcl | Propranolol Hcl | 22 | suppressed |
| Albuterol Sulfate Hfa | Albuterol Sulfate | 21 | suppressed |
| Venlafaxine Hcl Er | Venlafaxine Hcl | 21 | suppressed |
| Xarelto | Rivaroxaban | 21 | suppressed |
| Estradiol | Estradiol | 20 | suppressed |
| Folic Acid | Folic Acid | 20 | suppressed |
| Kerendia | Finerenone | 20 | suppressed |
| Risperidone | Risperidone | 20 | suppressed |
| Valsartan | Valsartan | 20 | suppressed |
| Glipizide | Glipizide | 19 | suppressed |
| Ramipril | Ramipril | 19 | suppressed |
| Breo Ellipta | Fluticasone/Vilanterol | 18 | suppressed |
| Solifenacin Succinate | Solifenacin Succinate | 18 | suppressed |
| Amlodipine Besylate-Benazepril | Amlodipine Besylate/Benazepril | 17 | suppressed |
| Basaglar Kwikpen U-100 | Insulin Glargine,hum.Rec.Anlog | 17 | suppressed |
| Buspirone Hcl | Buspirone Hcl | 17 | suppressed |
| Clonidine Hcl | Clonidine Hcl | 17 | suppressed |
| Entresto | Sacubitril/Valsartan | 17 | suppressed |
| Amoxicillin | Amoxicillin | 16 | suppressed |
| Armour Thyroid | Thyroid,pork | 16 | suppressed |
| Nano 2nd Gen Pen Needle | Pen Needle, Diabetic | 16 | suppressed |
| Rybelsus | Semaglutide | 16 | suppressed |
| Tresiba Flextouch U-200 | Insulin Degludec | 16 | suppressed |
| Benazepril Hcl | Benazepril Hcl | 15 | suppressed |
| Duloxetine Hcl | Duloxetine Hcl | 15 | suppressed |
| Fenofibrate | Fenofibrate | 15 | suppressed |
| Jardiance | Empagliflozin | 15 | suppressed |
| Nifedipine Er | Nifedipine | 15 | suppressed |
| Oxybutynin Chloride Er | Oxybutynin Chloride | 15 | suppressed |
| Propranolol Hcl Er | Propranolol Hcl | 15 | suppressed |
| Cephalexin | Cephalexin | 13 | 12 |
| Ciprofloxacin Hcl | Ciprofloxacin Hcl | 13 | 11 |
| Cyclobenzaprine Hcl | Cyclobenzaprine Hcl | 13 | suppressed |
| Suboxone | Buprenorphine Hcl/Naloxone Hcl | 13 | suppressed |
| Chlorthalidone | Chlorthalidone | 12 | suppressed |
| Isosorbide Mononitrate Er | Isosorbide Mononitrate | 12 | suppressed |
| Methylprednisolone | Methylprednisolone | 12 | 11 |
| Mupirocin | Mupirocin | 12 | 12 |
| Nitrofurantoin Mono-Macro | Nitrofurantoin Monohyd/M-Cryst | 12 | suppressed |
| Pioglitazone Hcl | Pioglitazone Hcl | 12 | suppressed |
| Ascomp With Codeine | Codeine/Butalbital/Asa/Caffein | 11 | suppressed |
| Bupropion Xl | Bupropion Hcl | 11 | suppressed |
| Enalapril Maleate | Enalapril Maleate | 11 | suppressed |
| Hydromorphone Hcl | Hydromorphone Hcl | 11 | suppressed |
| Ipratropium Bromide | Ipratropium Bromide | 11 | suppressed |
| Ropinirole Hcl | Ropinirole Hcl | 11 | suppressed |
| Triamcinolone Acetonide | Triamcinolone Acetonide | 11 | suppressed |
Timeline
Payment and prescribing data by year
Open Payments and Medicare Part D may refer to different years. They are shown separately rather than aligned as if they describe the same period.
| Year | General Payments | Main payer | Explicit products | Company overlaps | Part D coverage |
|---|---|---|---|---|---|
| 2025 | $1,261.03 · 34 records | Corcept Therapeutics | Auvelity, Cologuard Collection Kit, Dexcom G6 Transmitter, ELIQUIS, FREESTYLE LIBRE 3, GEMTESA, JOT DX, MOUNJARO, NEXLETOL, NP Thyroid 60, NURTEC ODT, Ozempic, REXULTI, Rybelsus, VOQUEZNA, Veozah, ZEPBOUND | 5 | — |
| 2024 | — | — | — | — | Complete |
Questions to ask
Questions you could discuss with your doctor
- What role, if any, does Eliquis play in your treatment recommendations for me?
- How do you evaluate evidence when you have a financial relationship with Lilly USA, LLC?
- Are there reasonable alternatives I should understand when we discuss treatment options?
- How should I interpret the industry-payment records shown here in the context of my care?
These are general questions generated from reviewed templates. They are not personalized medical advice.
Sources and limitations
How to read this page
- Payment and Medicare prescribing data can cover different years; every comparison shows both years explicitly.
- Part D does not represent a doctor’s entire practice; it excludes many patients and is subject to CMS public-release thresholds.
- Company–drug relationships must have an auditable source, a precise relationship type, and a valid evidence period. Unresolved mappings are not published.
- Generic drug claims are not attributed to a specific manufacturer without manufacturer-level evidence.
- When a source extract is incomplete, missing rows are never treated as proof of no payments or no prescriptions.
Loaded source releases
| Dataset | Year | Publication | Source |
|---|---|---|---|
| CMS Open Payments — General Payments | 2025 | 2026-06-30 | Original source |
| Medicare Part D Prescribers by Provider and Drug | 2024 | 2026-05-06 | Original source |
| NPPES Data Dissemination V2 | current / reference data | 2026-08-10 | Original source |
Full methodology · Questions & answers · Report a possible error